Roy Beveridge

2.1k citations

62 papers · 1.5k indexed · h-index 22

Impact in

Oncology top 5%
- Cancer Treatment and Pharmacology
- Neutropenia and Cancer Infections
Hematology top 5%
- Hematopoietic Stem Cell Transplantation

Papers in ⓘ

Oncology 31
- Cancer Treatment and Pharmacology 7
- Neutropenia and Cancer Infections 6
Geriatrics and Gerontology 3

Co-authors: Nancy E. Davidson (2 shared papers)Martin D. Abeloff (2 shared papers)J. Russell Hoverman (9 shared papers)Marcus A. Neubauer (5 shared papers)Michael Kolodziej (5 shared papers)Gary Gordon (1 shared paper)Robert M. Rifkin (5 shared papers)J. Cameron Muir (2 shared papers)
Journals: Journal of Clinical Oncology (12 papers)Journal of Oncology Practice (5 papers)Blood (4 papers)Journal of the National Comprehensive Cancer Network (3 papers)JNCI Journal of the National Cancer Institute (2 papers)
Partner nations: United States United Kingdom Romania

In The Last Decade

Roy Beveridge

61 papers receiving 1.4k citations

Peers

Countries citing papers authored by Roy Beveridge

Since Specialization

Citations

This map shows the geographic impact of Roy Beveridge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy Beveridge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy Beveridge more than expected).

Fields of papers citing papers by Roy Beveridge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roy Beveridge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy Beveridge. The network helps show where Roy Beveridge may publish in the future.

Co-authors

The 25 scholars most cited alongside Roy Beveridge, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Roy Beveridge Line = papers co-authored together Roy Beveridge links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 62 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Cost Effectiveness of Evidence-Based Treatment Guidelines for the Treatment of Non–Small-Cell Lung Cancer in the Community Setting Journal of Oncology Practice ·Marcus A. Neubauer, J. Russell Hoverman, Michael Kolodziej, Lonny Reisman, Stephen K. Gruschkus, Susan Nga Hoang, Albert A. Alva, Marilyn McArthur, Michael Forsyth, Todd Rothermel, Roy Beveridge	2010	140
2	High-Dose Chemotherapy With Reinfusion of Purged Autologous Bone Marrow Following Dose-Intense Induction as Initial Therapy for Metastatic Breast Cancer JNCI Journal of the National Cancer Institute ·M. J. Kennedy, Roy Beveridge, S. D. Rowley, Gary Gordon, Martin D. Abeloff, Nancy E. Davidson	1991	131
3	Integrating Palliative Care Into the Outpatient, Private Practice Oncology Setting Journal of Pain and Symptom Management ·J. Cameron Muir, Farrah N. Daly, Malene S. Davis, Richard L. Weinberg, Jessica Heintz, Thomas A. Paivanas, Roy Beveridge	2010	96
4	High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study The Lancet ·Raymond B. Weiss, Robert M. Rifkin, F. Marc Stewart, Richard L. Theriault, Lori Williams, Allen Herman, Roy Beveridge	2000	92
5	Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. Journal of Clinical Oncology ·D. W. Chan, Roy Beveridge, H Muss, Herbert A. Fritsche, Gabriel N. Hortobágyi, R Theriault, D. T. Kiang, B. J. Kennedy, Mike Evelegh	1997	88
6	Pathways, Outcomes, and Costs in Colon Cancer: Retrospective Evaluations in Two Distinct Databases Journal of Oncology Practice ·J. Russell Hoverman, Thomas H. Cartwright, Debra A. Patt, Janet L. Espirito, Matthew P. Clayton, Jody S. Garey, Terrance J. Kopp, Michael Kolodziej, Marcus A. Neubauer, Kathryn Fitch, Bruce Pyenson, Roy Beveridge	2011	83
7	Serum glycoproteins in cancer patients: First report of correlations within vitro andin vivo parameters of cellular immunity Cancer ·Arnold M. Baskies, Paul B. Chretien, Joseph F. Weiss, Robert Makuch, Roy Beveridge, William J. Catàlona, Herbert E. Spiegel	1980	69
8	Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma. Journal of Clinical Oncology ·Jean L. Grem, Emmet Jordan, Matthew Robson, Reinhard Binder, J. Michael Hamilton, Seth M. Steinberg, Susan G. Arbuck, Roy Beveridge, Arthur N. Kales, Julie Ann Miller	1993	59
9	Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. Journal of Clinical Oncology ·Esther M. John, Georgia B. Vogelsang, Roy Beveridge, ER Farmer, V Altomonte, A M Huelskamp, Nancy E. Davidson	1993	58
10	A Phase III, Randomized, Double-blind, Placebo-controlled, Multinational Trial of Iseganan for the Prevention of Oral Mucositis in Patients Receiving Stomatotoxic Chemotherapy (PROMPT-CT Trial) Leukemia & lymphoma ·Francis J. Giles, Carole B. Miller, David D. Hurd, John R. Wingard, Thomas R. Fleming, Stephen T. Sonis, Williamson Z. Bradford, Janis Pulliam, Elias Anaissie, Roy Beveridge, Mark M. Brunvand, Paul J. Martin, PROMPT-CT Trial Investigators†	2003	57
11	Caregiver Quality of Life After Autologous Bone Marrow Transplantation Cancer Nursing ·Deborah Boyle, Linda Blodgett, Sabine Gnesdiloff, Jackie White, Ann Marie Bamford, Michael Sheridan, Roy Beveridge	2000	46
12	Benchmarks for Value in Cancer Care: An Analysis of a Large Commercial Population Journal of Oncology Practice ·Michael Kolodziej, J. Russell Hoverman, Jody S. Garey, Janet L. Espirito, Sheetal Sheth, Aimee Ginsburg, Marcus A. Neubauer, Debra A. Patt, Barry Brooks, Charles S. White, Mark Sitarik, Roger T. Anderson, Roy Beveridge	2011	45
13	Randomized, Double-Blind, Multicenter Trial Comparing Clinafloxacin with Imipenem as Empirical Monotherapy for Febrile Granulocytopenic Patients Clinical Infectious Diseases ·D. J. Winston, Hillard M. Lazarus, Roy Beveridge, James W. Hathorn, Rasim Gucalp, Reuben Ramphal, Anthony W. Chow, W. G. Ho, R Horn, R. Feld, Thomas Louie, Mary Territo, Jeffrey L. Blumer, Kenneth J. Tack	2001	37
14	An Observational, Retrospective Analysis of Retreatment with Bortezomib for Multiple Myeloma Clinical Lymphoma & Myeloma ·Therese Conner, QuynhChau D. Doan, Ian Walters, Annette L. LeBlanc, Roy Beveridge	2008	36
15	The role of adjuvant therapy after resection of T1 N1 M0 and T2 N1 M0 non–small cell lung cancer Journal of Thoracic and Cardiovascular Surgery ·Mark K. Ferguson, Alex G. Little, Harvey M. Golomb, Philip C. Hoffman, Tom R. DeMeester, Roy Beveridge, David B. Skinner	1986	33
16	Sixteen-Week Dose-Intense Chemotherapy in the Adjuvant Treatment of Breast Cancer JNCI Journal of the National Cancer Institute ·Martin D. Abeloff, Roy Beveridge, Ross C. Donehower, J. H. Fetting, N. E. Davidson, Gary G. Gordon, William Waterfield, Dorothy Damron	1990	33
17	Impact of Long‐Acting Growth Factors on Practice Dynamics and Patient Satisfaction Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Roy Beveridge, Robert M. Rifkin, Ronald J. Moleski, Gary Milkovich, John Reitan, Thomas A. Paivanas, R. Jake Jacobs	2003	33
18	Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation Annals of Oncology ·Sergio Giralt, Kenneth F. Mangan, Richard T. Maziarz, Joseph Bubalo, Roy Beveridge, David D. Hurd, Floralyn Mendoza, E. B. Rubenstein, Timothy DeGroot, Michael W. Schuster	2010	30
19	A Phase II Trial of Autologous Bone Marrow Transplantation (ABMT) in Acute Leukemia with Edelfosine Purged Bone Marrow Advances in experimental medicine and biology ·William R. Vogler, Wolfgang E. Berdel, Robert B. Geller, Joel A. Brochstein, Roy Beveridge, William S. Dalton, Kenneth B. Miller, Hillard M. Lazarus	1996	26
20	Marijuana as an Antiemetic Drug: Journal of Addictive Diseases ·Richard H. Schwartz, Roy Beveridge	1994	25

About Roy Beveridge

Roy Beveridge is a scholar working on Oncology, Geriatrics and Gerontology, Hematology, Economics and Econometrics and Family Practice, having authored 62 papers that have together received 1.5k indexed citations. Recurring topics across this work include Economic and Financial Impacts of Cancer (11 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers), Cancer Treatment and Pharmacology (7 papers), Neutropenia and Cancer Infections (6 papers), Cancer Genomics and Diagnostics (4 papers), Nausea and vomiting management (4 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Childhood Cancer Survivors' Quality of Life (4 papers). The work is most often cited by research in Oncology (658 citations), Hematology (210 citations), Cancer Research (233 citations), Public Health, Environmental and Occupational Health (284 citations) and Pediatrics, Perinatology and Child Health (162 citations). Roy Beveridge has collaborated with scholars based in United States, United Kingdom and Romania. Frequent co-authors include Nancy E. Davidson, Martin D. Abeloff, J. Russell Hoverman, Marcus A. Neubauer, Michael Kolodziej, Gary Gordon, Robert M. Rifkin, J. Cameron Muir, Richard L. Weinberg and Richard L. Theriault. Their work appears in journals such as Journal of Clinical Oncology, Journal of Oncology Practice, Blood, Journal of the National Comprehensive Cancer Network and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact